Aclaris Therapeutics (ACRS) insider buying
12 open-market purchases of ACRS by Aclaris Therapeutics's executives and directors since August 2023, worth $5M in total, from SEC Form 4 filings.
The most recent: Anand Mehra bought $1M on November 19, 2024.
The biggest buyer over the period is Braden Michael Leonard: 10 purchases, $3M.
By year
| Year | Purchases | Value |
|---|---|---|
| 2024 | 11 | $4M |
| 2023 | 1 | $99,994 |
Biggest buyers
| Insider | Buys | Value |
|---|---|---|
| Braden Michael Leonard | 10 | $3M |
| Anand Mehra | 1 | $1M |
| James Loerop | 1 | $99,994 |
Every purchase
Newest first. From SEC Form 4 filings. Insider buying across the market.
| Date | Insider | Shares | Price | Value | Filing |
|---|---|---|---|---|---|
| Nov 19, 2024 | Anand Mehra |
666,666 | $2.25 | $1M | Form 4 |
| Jul 30, 2024 | Braden Michael Leonard |
173,730 | $1.30 | $225,849 | Form 4 |
| Jul 22, 2024 | Braden Michael Leonard |
17,716 | $1.33 | $23,562 | Form 4 |
| Jul 18, 2024 | Braden Michael Leonard |
130,317 | $1.30 | $169,412 | Form 4 |
| Jul 5, 2024 | Braden Michael Leonard |
123,017 | $1.15 | $141,470 | Form 4 |
| Jul 3, 2024 | Braden Michael Leonard |
143,288 | $1.16 | $166,214 | Form 4 |
| Jul 1, 2024 | Braden Michael Leonard |
107,434 | $1.14 | $122,475 | Form 4 |
| Jun 27, 2024 | Braden Michael Leonard |
235,000 | $1.15 | $270,250 | Form 4 |
| Jun 17, 2024 | Braden Michael Leonard |
150,000 | $1.13 | $169,500 | Form 4 |
| Jun 13, 2024 | Braden Michael Leonard |
528,621 | $1.15 | $607,914 | Form 4 |
| Jun 11, 2024 | Braden Michael Leonard |
1,000,000 | $1.08 | $1M | Form 4 |
| Aug 28, 2023 | James Loerop |
14,705 | $6.80 | $99,994 | Form 4 |
Questions
Are Aclaris Therapeutics insiders buying the stock?
12 open-market purchases of ACRS by Aclaris Therapeutics's executives and directors since August 2023, worth $5M in total, from SEC Form 4 filings. The most recent: Anand Mehra bought $1M on November 19, 2024.
What counts as insider buying here?
Open-market purchases (Form 4 code P) by officers and directors. Option exercises, grants and purchases by 10% owners are left out.
From Aclaris Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.